Identifying an appropriate PCV for use in Senegal, recent insights concerning Streptococcus pneumoniae NP carriage and IPD in Dakar

BMC Infectious Diseases

Benoit Garin³  Pascal Boisier⁴  Madeleine Ndour¹  Khady Seck²  Moussa Fafa Cissé⁶  Aliou Thiongane⁶  Mamadou Bâ⁶  Abdoulaye Seck⁵  Fatim Ba⁵ 

[1] Saint Martin Health Center, Dakar, Senegal;Medina Health Center, Dakar, Senegal;Bacteriology Laboratory, Pasteur Institute, Antananarivo, Madagascar;Epidemiology Units, Pasteur Institute, Yaounde, Cameroun;Medical Laboratory, Pasteur Institute, Dakar, Senegal;Pediatric Unit, Albert Royer Hospital, Dakar, Senegal

关键词: Senegal;    Sub-Saharan Africa;    Children;    Antibiotic resistance;    Serotypes;    Invasive pneumococcal disease;    Nasopharyngeal carriage;    Streptococcus pneumoniae;   

Others  :  1118212
DOI  :  10.1186/s12879-014-0627-8

 received in 2014-05-19, accepted in 2014-11-10,  发布年份 2014

【 摘 要 】

Background

Since 2000, the Global Alliance for Vaccines and Immunization (GAVI) and WHO have supported the introduction of the Pneumococcal Conjugate Vaccine (PCV) in the immunization programs of developing countries. The highest pneumococcal nasopharyngeal carriage rates have been reported (40-60%) in these countries, and the highest incidence and case fatality rates of pneumococcal infections have been demonstrated in Africa.

Methods

Studies concerning nasopharyngeal pneumococcal carriage and pneumococcal infection in children less than 5 years old were conducted in Dakar from 2007 to 2008. Serotype, antibiotic susceptibility and minimum inhibitory concentrations were determined. In addition, among 17 overall publications, 6 manuscripts of the Senegalese literature published from 1972 to 2013 were selected for data comparisons.

Results

Among the 264 children observed, 132 (50%) children generated a nasopharyngeal (NP) positive culture with Streptococcus pneumoniae. The five most prevalent serotypes, were 6B (9%), 19 F (9%), 23 F (7.6%), 14 (7.6%) and 6A (6.8%). Fifteen percent of the strains (20/132) showed reduced susceptibility to penicillin and 3% (4/132) showed reduced susceptibility to anti-pneumococcal fluoroquinolones. Among the 196 suspected pneumococcal infections, 62 (31.6%) Streptococcus pneumoniae were isolated. Serogroup 1 was the most prevalent serotype (21.3%), followed by 6B (14.9%), 23 F (14.9%) and 5 (8.5%). Vaccine coverage for PCV-7, PCV-10 and PCV-13, were 36.2% (17/47), 66% (31/47) and 70.2% (33/47) respectively. Reduced susceptibility to penicillin and anti-pneumococcal fluoroquinolones was 6.4% and 4.3%, respectively, and the overall lethality was 42.4% (14/33).

Conclusions

This study confirms a high rate of carriage and disease caused by Streptococcus pneumoniae serotypes contained within the current generation of pneumococcal conjugate vaccines and consistent with reports from other countries in sub-Saharan Africa prior to PCV introduction. Antimicrobial resistance in this small unselected sample confirms a low rate of antibiotic resistance. Case-fatality is high. Introduction of a high valency pneumococcal vaccine should be a priority for health planners with the establishment of an effective surveillance system to monitor post vaccine changes.

【 授权许可】

   
2014 Ba et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Martinelli D, Pedalino B, Cappelli M, Caputi G, Sallustio A, Fortunato F, Tafuri S, Cozza V, Germinario C, Chironna M, Prato R: Towards the 13-valent pneumococcal conjugate universal vaccination: effectiveness in the transition era between PCV7 and PCV13 in Italy, 2010–2013. Hum Vaccin Immunother 2014, 10(1):33-39.
• [2]Zuccotti G, Mameli C, Daprai L, Garlaschi ML, Dilillo D, Bedogni G, Faccini M, Gramegna M, Torresani E, Emanuela B, Annarita B, Milena B, Dorella B, Manuela B, Ballerini E, Benincaso A, Bonvissuto M, Bricali D, Brioschi M, Calloni CS, Camiletti MI, Colella G, De Angelis L, Decarlis S, Di Nello F, Dozzi M, Galli E, Gandini V, Giuliani MG, et al.: Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from healthy children in the 13-valent pneumococcal conjugate vaccine era. Vaccine 2014, 32:527-534.
• [3]Ayieko P, Griffiths UK, Ndiritu M, Moisi J, Mugoya IK, Kamau T, English M, Scott JAG: Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children.PLoS Negl Trop Dis 2013, 8(6):e67324.
• [4]Hammitt L, Akech D, Morpeth S, Karani A, Kihuha N, Nyongesa S, Bwanaali T, Mumbo E, Kamau T, Sharif SK, Scott JA: Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Health 2014, 2(7):397-405.
• [5]Mehr S, Wood N: Streptococcus pneumoniae – a review of carriage, infection, serotype replacement and vaccination. Paediatric Resp Rev Elsevier Ltd 2012, 13:258-264.
• [6]Wang SA, Mantel CF, Gacic-Dobo M, Dumolard L, Cherian T, Flannery B, Loo JD, Verani JR, Whitney CG: Progress in introduction of pneumococcal conjugate vaccine Worldwide, 2000–2012. MMWR 2013, 62(16):308-311.
• [7]Egere U, Townend J, Roca A, Akinsanya A, Bojang A, Nsekpong D, Greenwood B, Adgbola RA, Hill PC: Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal carriage in newborns in rural Gambia: a randomised controlled trial.PLoS One 2012, 7(11):e49143.
• [8]Odutola A, Antonio M, Owolabi O, Bojang A, Foster-Nyarko E, Donkor S, Adetifa I, Taylor S, Bottomley C, Greenwood B, Ota M: Comparison of the prevalence of common bacterial pathogens in the oropharynx and nasopharynx of Gambian infants.PLoS One 2013, 8(9):e75558.
• [9]Simell B, Auranen K, Käyhty H, Goldblatt D, Dagan R, O’Brien KL: The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines 2012, 11(7):841-855.
• [10]Bogaert D, Groot R: De, Hermans PWM: Streptococcus pneumoniae colonisation : the key to pneumococcal disease. Lancet Infect Dis 2004, 4:144-148.
• [11]Shak JR, Vidal JE, Klugman KP: Influence of bacterial interactions on pneumococcal colonization of the nasopharynx. Trends Microbiol 2013, 21(3):129-135.
• [12]O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T: Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902.
• [13]Donkor ES: Molecular typing of the pneumococcus and its application in epidemiology in sub-Saharan Africa. Front Cell Infect Microbiol 2013, 3:1-5.
• [14]Donkor ES, Dayie TKDN, Badoe VE: Vaccination against pneumococcus in West africa: perspectives and prospects. Int J Gen Med 2013, 6:757-764.
• [15]Adegbola RA, Deantonio R, Hill PC, Roca A, Usuf E, Hoet B, Greenwood BM: Carriage of Streptococcus pneumoniae and Other Respiratory Bacterial Pathogens in Low and Lower- Middle Income Countries : A Systematic Review and Meta-Analysis.PLoS One 2014, 9(8).
• [16]Steers E, Foltz E, Graves B: An inocula replicating apparatus for routine testing of bacterial susceptibility to antibiotics. Antibiot Chemother 1959, 9(5):307-311.
• [17]Echave P, Bille J, Audet C, Talla I, Vaudaux B, Gehri M: Percentage, Bacterial Etiology and Antibiotic Susceptibility of Acute Respiratory Infection and Pneumonia among Children in Rural Senegal. J Trop Pediatr 2003, 49:28-32.
• [18]Baylet R, Diop S, Dauchy S, Roulet H, Baylet JF: Infections bactériennes et virales à transmission RP dans deux populations Sérères. Bull Soc Path Ex 1983, 76:16-20.
• [19]Diop Mar I, Denis F, Cadoz M: Epidémiologie des méningites à pneumocoque en Afrique. Aspects cliniques et sérotypiques. Path Biol 1979, 27:543-548.
• [20]Cadoz M, Denis F, Diop Mar I: Etude épidémiologique des cas de méningites purulentes hospitalisées a Dakar pendant la décennie 1970–1979. Bull Org Mondiale Santé 1981, 59(4):575-584.
• [21]Ba O, Fleming JA, Dieye Y, Mutombo B, Ba M, Cisse MF, Diallo AG, Sow I, Slack MPE, Faye PC, Ba M, Diallo N, Weiss NS: Hospital Surveillance of Childhood Bacterial Meningitis in Senegal and the Introduction of Haemophilus influenzae Type b Conjugate Vaccine. Am J Trop Med Hyg 2010, 83(6):1330-1335.
• [22][http://dx.doi.org/10.1016/j.medmal.2013.06.006.] webcite Dia ML, Sonko MA, Kâ R, Bâ M, Cissé MF: Serotype and antimicrobial susceptibility patterns of Streptococcus pneumoniae isolates in Senegal between 1996 and 2010.Med Mal Infect 2013,
• [23]Abdullahi O, Karani A, Tigoi CC, Mugo D, Kungu S, Wanjiru E, Jomo J, Musyimi R, Lipsitch M, Scott JAG: The Prevalence and Risk Factors for Pneumococcal Colonization of the Nasopharynx among Children in Kilifi District, Kenya.PLoS One 2012, 7(2):e30787.
• [24]Adetifa IMO, Antonio M, Okoromah CAN, Ebruke C, Inem V, Nsekpong D, Bojang A, Adegbola RA: Pre-Vaccination Nasopharyngeal Pneumococcal Carriage in a Nigerian Population: Epidemiology and Population Biology.PLoS One 2012, 7(1):e30548.
• [25]Mueller JE, Yaro S, Ouedrago MS, Levina N, Njanpop-Lafourcade BM, Tall H, Idohou RS, Sanou O, Kroman SS, Drabo A, Nacro B, Millogo A, van der Linen M, Gessner BD: Pneumococci in the African Meningitis Belt: Meningitis Incidence and Carriage Prevalence in Children and Adults.PLoS One 2012, 7(12):e52464.
• [26]Dayie NTKD, Arhin RE, Newman MJ, Dalsgaard A, Bisgaard M, Frimodt-Møller N, Slotved HC: Penicillin resistance and serotype distribution of Streptococcus pneumoniae in Ghanaian children less than six years of age. BMC Infect Dis 2013, 13:490-497. BioMed Central Full Text
• [27]Gessner BD, Sanou O, Drabo A, Tamekloe , Tsidi A, Yaro S, Tall H, Moisi JC, Mueller JE, Njanpop-LaFourcade BM: Pneumococcal serotype distribution among meningitis cases from Togo and Burkina Faso during 2007–2009. Vaccine 2012, 30(Suppl):41-45.
• [28]Ginsburg S, Tinkham L, Riley K, Kay NA, Klugman KP, Gill CJ: Antibiotic non-susceptibility among Streptococcus pneumoniae and Haemophilus influenzae isolates identified in African cohorts : a meta-analysis of three decades of published studies. Int J Antimicrob Agents [Internet] Elsevier BV 2013, 42(6):482-491. Available from: http://dx.doi.org/10.1016/j.ijantimicag.2013.08.012
• [29]Anagaw B, Gezachew M, Biadgelgene F, Anagaw B, Geleshe T, Taddese B, Getie B, Endris M, Mulu A, Unakal C: Antimicrobial susceptibility patterns of Streptococcus pneumoniae over 6 years at Gondar University Hospital, Northwest Ethiopia. Asian Pac J Trop Biomed 2013, 3(7):536-541.
• [30]Flasche S, Van Hoek AJ, Sheasby E, Waight P, Andrews N, Sheppard C, George R, Miller E: Effect of Pneumococcal Conjugate Vaccination on Serotype-Specific Carriage and Invasive Disease in England: A Cross-Sectional Study.Plos Med 2011, 8(4):e1001017.
• [31]Nurhonen M, Cheng AC, Auranen K: Pneumococcal Transmission and Disease In Silico : A Microsimulation Model of the Indirect Effects of Vaccination.Plos One 2013, 8(2).